Zenas Biopharma (NASDAQ:ZBIO) has entered into a licensing agreement with InnoCare Pharma (USOTC:INCPF), securing global rights to three autoimmune disease candidates from InnoCare’s development portfolio.
The collaboration includes orelabrutinib, a BTK inhibitor currently in Phase 3 clinical trials for the treatment of multiple sclerosis.
Additionally, the deal grants Zenas access to two early-stage assets — a novel oral IL-17AA/AF inhibitor and an oral, brain-penetrant TYK2 inhibitor — both of which are expected to enter Phase 1 testing in 2026.
Under the terms of the agreement, Zenas will make upfront and near-term milestone payments totaling up to $100 million in cash to InnoCare.
In a separate announcement, Zenas Biopharma revealed it had successfully raised $120 million through a private placement financing, further strengthening its balance sheet as it advances its autoimmune and inflammatory disease pipeline.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.